Close

Ingles

Famotidine Aids in COVID-19 by Helping Limit Inflammation

Researchers have discovered just how the antacid famotidine, commonly sold as Pepcid by a Johnson & Johnson unit, was able to help alleviate COVID-19 symptoms in clinical trials. In studies in mice, they found that famotidine stimulates the vagus nerve, which controls the immune system and other involuntary body functions. […]

Read More

COVID-19 insights: Waning immunity will impact long-range forecasts

The latest takeaways from IHME: Regional updates: China continues the zero-COVID strategy and reports no increase in cases. South Africa may be reaching a peak of the BA.4/BA.5 winter surge. The United States is experiencing an increase in Omicron cases – likely due to behavioral changes, and possibly due to […]

Read More

Post–COVID Conditions Among Adult COVID-19 Survivors Aged 18–64 and ≥65 Years — United States, March 2020–November 2021

Summary What is already known about this topic? As more persons are exposed to and infected by SARS-CoV-2, reports of patients who experience persistent symptoms or organ dysfunction after acute COVID-19 and develop post-COVID conditions have increased. What is added by this report? COVID-19 survivors have twice the risk for […]

Read More

Measuring the availability of human resources for health and its relationship to universal health coverage for 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019

Summary Background Human resources for health (HRH) include a range of occupations that aim to promote or improve human health. The UN Sustainable Development Goals (SDGs) and the WHO Health Workforce 2030 strategy have drawn attention to the importance of HRH for achieving policy priorities such as universal health coverage […]

Read More

Nucleocapsid Antibodies Appear to Be Long-Lasting After SARS-CoV-2 Infection

In a prospective, longitudinal study, N-antibodies peaked 90–100 days after infection and persisted for at least 500 days in most patients. The duration of antibody response after SARS-CoV-2 infection is not clearly established, although prior studies have estimated that antibodies produced after natural infection last from 3 to 6 months. […]

Read More

1 in 8 Develop Myocarditis Post COVID-19 Hospitalisation

In the largest study of its kind to date researchers have found that 1 in 8 people hospitalised with COVID-19 subsequently developed myocarditis, with the severity of infection most closely linked to the severity of long-COVID symptoms. For the new prospective cohort study, led by the University of Glasgow in […]

Read More

Estrogen Treatment Linked to Reduced COVID Mortality

Women who went on hormone replacement therapy (HRT) with estrogen within six months of catching COVID-19 had a reduced risk of dying, a new study says. The study, coupled with data showing men have higher hospitalization and mortality rates from COVID than women, provides more evidence that estrogen may offer broad protection against the […]

Read More

SARS-CoV-2 Could Be at Root of Mysterious Hepatitis in Kids

 A chain of events possibly triggered by unrecognized infection with the SARS-CoV-2 coronavirus could be causing the mysterious cases of severe hepatitis reported in hundreds of young children around the world, researchers suggest. Children with COVID-19 are at significantly increased risk for liver dysfunction afterward, according to a report posted […]

Read More

Pancreatic Involvement in COVID-19: What Do We Know?

There is increasing evidence of the impact that SARS-CoV-2 infection has on patients with diabetes. It involves the relationship between COVID-19 and new diagnoses of diabetes and blood glucose disorders, among others, in the post–COVID-19 period. These topics were addressed at the XXXIII National Congress of the Spanish Diabetes Society […]

Read More
Translate »